The agency might dissuade patients from participating in a crucial part of our research-and-development system.
The nucleic acid therapeutics market is growing due to rising genetic and chronic disease prevalence, expanding genomics R&D, ...
Zacks Investment Research on MSN
Should You Buy Moderna Stock Ahead of Q3 Earnings Report?
Moderna MRNA is set to report third-quarter 2025 earnings on Nov. 6, before the opening bell. The Zacks Consensus Estimate ...
ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...
Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...
The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...
Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...
The new Moderna COVID vaccine, mNexspike, is approved for adults 65 and older and people 12 to 64 with an underlying medical ...
SHELTON, CT / ACCESS Newswire / October 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the ...
Baron Health Care Fund gained for the quarter and outperformed its benchmark, the Russell 3000 Health Care Index. Read more ...
Moderna's experimental vaccine for cytomegalovirus, a cause of disability in newborns, failed in a Phase 3 trial ...
New and changing FDA and CDC guidance on COVID-19 vaccine eligibility has left many confused. Here's what to know about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback